ABOUT US
Mission
History
Boards of Directors
Staff
Join PPTA
MEMBER COMPANIES
ISSUES
U.S.
Federal
State
Regulatory
European Union
Patient Access & Health Policy
Institutions
EU Member States
Other Countries
Organizations and Institutions
International
International Institutions
PLASMA & THERAPIES
Plasma & Blood
Become a Donor
Find a Donation Center
FAQ
Diseases
Therapies
PROGRAMS & STANDARDS
Donor Deferral (NDDR)
Patient Notification System
IQPP
QSEAL
Data Center
NEW! PPTA DHQ
PATIENT RESOURCES
Learn About Patients
Patient Groups
Patient Notification System
Resources
IVIG Manufacturers
PUBLICATIONS
The Source
This Season's Issue
Why Subscribe?
Subscription / Order Center
Email the Editor
Advertising Opportunities
Fact Sheets
Brochures
NEWSROOM
Calendar of Events
Press Releases
Industry Facts
Videos
Press Contacts
Subscribe to e-releases
CONTACT
PATIENT NOTIFICATION SYSTEM
Confidential notification within 24 hours of therapy withdrawals & recalls
China
USA/UK
Spain
Germany
Italy
Japan
France
Home
>
Issues
>
U.S.
>
State
Print
Email
U.S. State Issues
Access to Therapies
PPTA works with member companies and stakeholders to obtain access to therapies, payer cost containment strategies and on issues centered around health care reform.
Comment Letters
PPTA Letter to The Honorable Beverly Earle, North Carolina House of Representatives, Regarding the Appropriations Act (SB 897)
(June 2010)
PPTA Letter to The Honorable Fran Pavley, California State Senate Regarding Support for SB 971
(February 2010)
PPTA Letter to The Honorable Ron Richard, Speaker of the House, Missouri Regarding Support for HB 1525
(February 2010)
PPTA Letter to the Chairmen of the Joint Committee on Public Health In Massachusetts Regarding Support for HB 2098, an Act Relevant to the Treatment of Hemophilia
(November 2009)
PPTA Letter to Illinois Governor Pat Quinn Regarding Support for the Bleeding Disorders Community
(May 2009)
PPTA Comment Letter to the DC Department of Health; Proposed Rule Creating Chapter 17, Pharmaceutical Education Program, of Title 22, of the District of Columbia Municipal Regulations
(August 2008)
PPTA Support Letter to the Massachusetts Senate Health Care Financing Committee; H. 4574 Vital Legislation for the Bleeding Disorders Community
(July 2008)
PPTA Support Letter to the California Assembly Budget Sub-Committee on Proposed Budget Trailer Bill Language
(May 2008)
PPTA Comment Letter to the
California
Senate Health Committee; SB 1594, the “Hemophilia Standards of Care Act”
(March 2008)
PPTA Comment Letter to
the California Board of Pharmacy Regarding Delay Implementation of California’s Pedigree Requirements
(March 2008)
PPTA Comment Letter to
the California Board of Pharmacy Regarding Pedigree Law Implementation
(December 2007)
State of Alabama Response to PPTA on Alabama Medicaid Program Decision to Implement Changes In Reimbursement of Hemophilia Factor VIII Therapie
s (November 2007)
PPTA Letter to Office of Pharmacy in State of West Virginia on Reimbursement for A1P1 Products
(October 2007)
PPTA Support Letter for H.2155 and H.2071 on Vital Legislation for the Bleeding Disorders Community in Massachusetts
(September 2007)
PPTA Letter to Pennsylvania House Insurance Committee Chairman for the Enactment of HB 1105, the "Hemophilia Standards of Care Act"
(June 2007)
PPTA Comment Letter to Arkansas Medicaid Policy Program on Arkansas Hemophilia Management Program
(June 2007)
PPTA Comment Letter to Arizona Senate Committee on Health – IVIG hearing Update
(March 2007)
PPTA Comment letter on Deficit Reduction Act of 2005
(February 2007)
PPTA Comment Letter to State of Alabama on Medicaid Program Decision to Implement Public Health Service Based Pricing for Reimbursement of Hemophilia Factor VIII Therapies
(January 2007)
Payer Cost Containment Strategies
PPTA remains committed to preventing cost containment measures from impacting patient access to life-saving therapies. Payers frequently use cost containment measures to reduce the impact of rising health care costs. Common strategies include reducing pharmacy reimbursement, requiring patient cost-sharing, and single source provider agreements.
West Virginia Office of Pharmacy Services Response to PPTA on Reimbursement rate for alpha-1 proteinase inhibitors
(December 2007)
PPTA Comment Letter to the Florida Chairman, HHS Appropriations Regarding Support the Alpha One Screening and Detection Program
(April 2008)
PPTA Comment Letter to the Kentucky Office of Legal Services on the Department for Medicaid Services’ Proposed Administrative Regulation Hemophilia Treatment Reimbursement and Coverage Via the 340B Drug Pricing Program 907 K.A.R. 3:205
(September 2008)
Impact of Medicaid Reimbursement - Issue Brief
(October 2007)
Healthcare Reform
There are more than 45 million individuals in the United States that lack health insurance. Many states are discussing healthcare reform to address the problem of the uninsured in their state. PPTA will actively participate in these discussions to ensure that the unique health care needs of plasma protein therpaies consumers are addressed.
PPTA Comments on Texas Medicaid Reform Proposal
(December 2007)
Proclamations, Resolutions and Legislation
Minnesota SB339:
Standards of Care Bill 2009
. Descriptions of
alpha-1 antitrypsin deficiency
,
primary immunodeficiency diseases
and
von Willebrand Disease
.
Minnesota: Proclamation the Month of May 2008 as Plasma Protein Therapies Month
Minnesota:
SF2290
and
HF3013
, “A bill for an act relating to health; requiring coverage of plasma protein treatments; amending Minnesota Statutes 2006, section 256B.0625, by adding a subdivision; proposing coding for new law in Minnesota Statutes, chapter 144A
Florida – Senate Resolution Recognizing April 2007 as Plasma Protein Therapies Month
Maine – Joint Resolution Establishing March as Access to Plasma Protein Therapies Month
Minnesota – Proclamation the month of May 2007 as Plasma Protein Therapies Month
Texas – State Resolution Recognizing June 2007 Be Recognized as IVIG Awareness Month
State Advocacy Handbook
In addition to the following information, consumer groups also should visit the
State Advocacy Handbook
. PPTA developed this resource to help consumer groups advocated for patient access in their states and to provide information about key issues facing users of plasma protein therapies.